ストックスクリーナーアプリを入手
1.50
1.96%
-0.03
プレマーケット:
1.44
-0.06
-4.00%
前日終値:
$1.53
開ける：
$1.5
24時間の取引高:
315.73K
Relative Volume:
0.14
時価総額：
$20.68M
収益：
-
当期純損益:
$-8.83M
株価収益率:
-1.8973
EPS:
-0.7906
ネットキャッシュフロー:
$-8.61M
1週間 パフォーマンス:
+4.17%
1か月 パフォーマンス:
+45.63%
6か月 パフォーマンス:
+42.86%
1年 パフォーマンス:
+11.94%
1日の値動き範囲:
$1.4601
$1.54
1週間の範囲:
$1.17
$1.54
52週間の値動き範囲:
$0.8588
$2.67
Cocrystal Pharma Inc Stock (COCP) Company Profile
名前
Cocrystal Pharma Inc
セクター
電話
(786) 459-1831
住所
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.50 | 21.09M | 0 | -8.83M | -8.61M | -0.7906 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-08 | 開始されました | H.C. Wainwright | Buy |
Cocrystal Pharma Inc (COCP) 最新ニュース
Smart Money: Can Cocrystal Pharma Inc deliver consistent EPS growth2026 Technical Patterns & Daily Growth Stock Tips - baoquankhu1.vn
Why Cocrystal Pharma Shares Are Cooling Off Monday? - MSN
COCP stock soars 75% — what is the link to Cocrystal’s norovirus treatment? - MSN
Investor Mood: Is Cocrystal Pharma Inc benefiting from innovation trendsQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Tech Rally: Is Cocrystal Pharma Inc stock risky to hold nowMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention - Zacks Small Cap Research
Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance UK
COCP PE Ratio & Valuation, Is COCP Overvalued - Intellectia AI
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - Yahoo Finance
Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight - meyka.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988 - Sahm
FDA grants fast track status to Cocrystal’s norovirus drug By Investing.com - Investing.com Australia
Cocrystal Pharma stock surges on FDA Fast Track designation By Investing.com - Investing.com South Africa
Cocrystal Pharma (COCP) Receives FDA Fast Track Status for Norov - GuruFocus
Cocrystal Pharma stock surges on FDA Fast Track designation - Investing.com
Cocrystal Pharma, Inc. (8CC.F) stock price, news, quote and history - Yahoo Finance UK
Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom - StocksToTrade
Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug - TipRanks
COCP Stock Soars 75% — What Is The Link To Cocrystal’s Norovirus Treatment? - Stocktwits
Cocrystal Pharma Advances Antiviral Trials Amid Financial Strategy Shift - timothysykes.com
FDA grants fast track status to Cocrystal’s norovirus drug - Investing.com
FDA Fast Track backs Cocrystal (Nasdaq: COCP) oral norovirus antiviral CDI-988 - Stock Titan
Cocrystal Pharma, Inc. announced that its antiviral candidate drug Cdi-988 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). - Bitget
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - GlobeNewswire
COCP gets FDA Fast Track for CDI-988 norovirus drug, stock up 75% | Tap to know more | Inshorts - Inshorts
Cocrystal begins norovirus challenge study, reports 2025 results By Investing.com - Investing.com South Africa
Cocrystal Pharma Reports 2025 Financial Results and Advances Norovirus and Influenza Antiviral Drug Pipeline - Minichart
Cocrystal Pharma 2025 Research and Development Expenses $5.1M >COCP - Moomoo
Cocrystal Pharma Reports 2025 Financial Results, Advances Antiviral Drug Programs - National Today
Cocrystal Pharma Reports 2025 Financial Results - National Today
[10-K] Cocrystal Pharma, Inc. Files Annual Report - Stock Titan
Cocrystal begins norovirus challenge study, reports 2025 results - Investing.com
Cocrystal Pharma 2025 10-K: $0 Revenue, $(0.78) EPS, $(8.83)M Net Loss - TradingView
Cocrystal Pharma reports 2025 net loss $8.8M, cash $7.7M, advances norovirus CDI-988 into Phase 1b - TradingView — Track All Markets
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cocrystal Pharma (NASDAQ: COCP) cuts 2025 loss to $8.8M and advances antivirals - Stock Titan
Cocrystal Pharma, Inc. recently released its financial report for fiscal year 2025 and provided an update on the latest progress in its antiviral drug development projects. - Bitget
Cocrystal Pharma 2025 net loss narrows as R&D expenses fall - TradingView
BRIEF-Cocrystal Pharma FY Net Income USD -8.831 Million - TradingView — Track All Markets
No approved norovirus drug exists. Cocrystal now tests one in humans - Stock Titan
Form 8-KCurrent report - ADVFN
Institution Moves: Can Cocrystal Pharma Inc ride the EV waveEarnings Recap Report & Real-Time Volume Surge Alerts - baoquankhu1.vn
Cocrystal Pharma Inc (COCP) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):